Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

(2010) J. J. Hwang et al.   CLINICAL CANCER RESEARCH

Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells

(2010) Amandine Chaix et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Moonlighting protein in Starkeyomyces koorchalomoides: Characterization of dihydrolipoamide dehydrogenase as a protein acetyltransferase utilizing acetoxycoumarin as the acetyl group donor

(2009) Tapesh K. Tyagi et al.   BIOCHIMIE

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

(2009) G. Chan et al.   BLOOD

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

(2009) K. J. Aichberger et al.   BLOOD

Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality

(2009) D. Schmidt-Arras et al.   BLOOD

Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3

(2009) Kristina Masson et al.   CELLULAR SIGNALLING

Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes

(2009) Chunaram Choudhary et al.   MOLECULAR CELL

Ezrin is a target for oncogenic Kit mutants in murine erythroleukemia

(2008) R. Monni et al.   BLOOD

Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade

(2008) N. Harir et al.   BLOOD

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL

(2008) F. E. Boccalatte et al.   BLOOD

The tyrosine phosphatase Shp2 (PTPN11) in cancer

(2008) Gordon Chan et al.   CANCER AND METASTASIS REVIEWS

A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

(2008) A. D. Schimmer et al.   CLINICAL CANCER RESEARCH

Acquired resistance to tyrosine kinase inhibitors during cancer therapy

(2008) Jeffrey A Engelman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS